JP2024050581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024050581A5 JP2024050581A5 JP2024000757A JP2024000757A JP2024050581A5 JP 2024050581 A5 JP2024050581 A5 JP 2024050581A5 JP 2024000757 A JP2024000757 A JP 2024000757A JP 2024000757 A JP2024000757 A JP 2024000757A JP 2024050581 A5 JP2024050581 A5 JP 2024050581A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- formulation
- sustained release
- weight
- hpmc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 45
- 238000009472 formulation Methods 0.000 claims 37
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 24
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 24
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 24
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 24
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 22
- 238000013268 sustained release Methods 0.000 claims 21
- 239000012730 sustained-release form Substances 0.000 claims 21
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 16
- 239000011230 binding agent Substances 0.000 claims 16
- 229960001021 lactose monohydrate Drugs 0.000 claims 16
- 229960001338 colchicine Drugs 0.000 claims 11
- 206010027476 Metastases Diseases 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 10
- 230000009401 metastasis Effects 0.000 claims 10
- 230000004614 tumor growth Effects 0.000 claims 10
- 229920000881 Modified starch Polymers 0.000 claims 8
- 235000021355 Stearic acid Nutrition 0.000 claims 8
- 239000008187 granular material Substances 0.000 claims 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000007921 spray Substances 0.000 claims 8
- 239000008117 stearic acid Substances 0.000 claims 8
- 239000000454 talc Substances 0.000 claims 8
- 229910052623 talc Inorganic materials 0.000 claims 8
- 230000002519 immonomodulatory effect Effects 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 206010073069 Hepatic cancer Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010061269 Malignant peritoneal neoplasm Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 230000006023 anti-tumor response Effects 0.000 claims 2
- 201000000053 blastoma Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000008184 embryoma Diseases 0.000 claims 2
- 230000002357 endometrial effect Effects 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000006759 inflammatory activation Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000002524 peritoneal carcinoma Diseases 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025096574A JP2025134752A (ja) | 2018-02-02 | 2025-06-10 | 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625354P | 2018-02-02 | 2018-02-02 | |
| US62/625,354 | 2018-02-02 | ||
| PCT/EP2019/052492 WO2019149884A1 (en) | 2018-02-02 | 2019-02-01 | Use of colchicine to inhibit tumor growth and metastases |
| JP2020541560A JP2022514997A (ja) | 2018-02-02 | 2019-02-01 | 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541560A Division JP2022514997A (ja) | 2018-02-02 | 2019-02-01 | 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025096574A Division JP2025134752A (ja) | 2018-02-02 | 2025-06-10 | 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024050581A JP2024050581A (ja) | 2024-04-10 |
| JP2024050581A5 true JP2024050581A5 (enExample) | 2024-06-26 |
Family
ID=65278359
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541560A Ceased JP2022514997A (ja) | 2018-02-02 | 2019-02-01 | 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用 |
| JP2024000757A Pending JP2024050581A (ja) | 2018-02-02 | 2024-01-05 | 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用 |
| JP2025096574A Pending JP2025134752A (ja) | 2018-02-02 | 2025-06-10 | 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541560A Ceased JP2022514997A (ja) | 2018-02-02 | 2019-02-01 | 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025096574A Pending JP2025134752A (ja) | 2018-02-02 | 2025-06-10 | 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11534415B2 (enExample) |
| EP (1) | EP3746061A1 (enExample) |
| JP (3) | JP2022514997A (enExample) |
| CN (1) | CN111954524A (enExample) |
| CA (1) | CA3089781A1 (enExample) |
| EA (1) | EA202091736A1 (enExample) |
| WO (1) | WO2019149884A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021089715A1 (en) * | 2019-11-06 | 2021-05-14 | Murray And Poole Enterprises, Ltd. | Use of colchicine in the treatment and prevention of lung cancer |
| CN115068483B (zh) * | 2021-03-16 | 2023-10-31 | 中国科学院上海药物研究所 | Mln4924在缓解秋水仙碱中毒中的新用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
| US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
| US3546142A (en) | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
| US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
| US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
| US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
| CA2286477A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| CN1748671A (zh) * | 2005-08-30 | 2006-03-22 | 孔庆忠 | 含抗有丝分裂药物的缓释注射剂 |
| CN101485637B (zh) * | 2008-01-18 | 2011-03-30 | 普尔药物科技开发（深圳）有限公司 | 秋水仙碱骨架控释片或胶囊 |
| ES2900740T3 (es) | 2012-11-02 | 2022-03-18 | Murray & Poole Entpr Ltd | Tratamiento o prevención de episodios cardiovasculares mediante la administración de colchicina |
| WO2014170755A2 (en) * | 2013-04-16 | 2014-10-23 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
| JP2016540042A (ja) | 2013-11-05 | 2016-12-22 | コグネート バイオサービシズ， インコーポレイテッド | がんを処置するためのチェックポイント阻害剤および治療薬の組合せ |
-
2019
- 2019-02-01 US US16/966,892 patent/US11534415B2/en active Active
- 2019-02-01 CA CA3089781A patent/CA3089781A1/en active Pending
- 2019-02-01 WO PCT/EP2019/052492 patent/WO2019149884A1/en not_active Ceased
- 2019-02-01 EP EP19703061.2A patent/EP3746061A1/en active Pending
- 2019-02-01 JP JP2020541560A patent/JP2022514997A/ja not_active Ceased
- 2019-02-01 EA EA202091736A patent/EA202091736A1/ru unknown
- 2019-02-01 CN CN201980023515.4A patent/CN111954524A/zh active Pending
-
2022
- 2022-12-26 US US18/088,692 patent/US11877991B2/en active Active
-
2023
- 2023-12-09 US US18/534,576 patent/US20240099999A1/en active Pending
-
2024
- 2024-01-05 JP JP2024000757A patent/JP2024050581A/ja active Pending
-
2025
- 2025-06-10 JP JP2025096574A patent/JP2025134752A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024050581A5 (enExample) | ||
| CN102740851B (zh) | Pi3k抑制剂和mek抑制剂的组合 | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| KR20170084034A (ko) | 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도 | |
| KR20160048807A (ko) | 과증식성 질병의 치료에서 사용하기 위한 mek 억제제 및 erk 억제제의 조합 | |
| JP2020105190A5 (enExample) | ||
| JP2019527231A5 (enExample) | ||
| Cheng et al. | Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib. | |
| KR20140129164A (ko) | 히스톤 데아세틸라아제 억제제 및 파조파닙의 조합물 및 이의 용도 | |
| CN102579454B (zh) | 治疗肿瘤疾病的药物组合物 | |
| JPWO2022269525A5 (enExample) | ||
| CN115414351B (zh) | pladienolide B与PD-L1抗体组合在肿瘤免疫治疗领域的应用 | |
| JP2017530143A5 (enExample) | ||
| JP2020526594A (ja) | Ｐｄ−１を標的とするサポニン系化合物及びその応用 | |
| CN104602691B (zh) | Vegfr‑3抑制剂用于治疗肝细胞癌的用途 | |
| Escudier et al. | Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma | |
| JP5890310B2 (ja) | 組合せ | |
| CA2569132A1 (en) | Cancer treatment method | |
| KR20190026755A (ko) | 암의 치료를 위한 유지 요법 | |
| CN115243719A (zh) | CTB006与Ponatinib联合应用 | |
| WO2020083187A1 (zh) | 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途 | |
| Aggarwal et al. | 341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC) | |
| JP4091639B2 (ja) | チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および／または処置剤 | |
| JP2023504114A (ja) | 置換ブテンアミドの応用 | |
| JP2020090484A (ja) | エルロチニブを有効成分とする医薬錠剤 |